Zacks Investment Research upgraded shares of SciSparc (NASDAQ:SPRC – Get Rating) from a hold rating to a strong-buy rating in a research note released on Tuesday morning, Zacks.com reports. The firm currently has $4.50 price objective on the stock. According to Zacks, “SciSparc Ltd. is a specialty clinical-stage pharmaceutical company. It focuses on the development […]
SciSparc to Commence Phase IIa Clinical Trial of SCI-110 for the Treatment of Alzheimer s Disease and Agitation
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
A Complete List Of NYSE And NASDAQ-Listed Cannabis Companies (Updated)
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.